Qiagen (QGEN) Q3 2026 earnings review
Qiagen beats quarterly targets and agrees to EQT buyout
Qiagen, a maker of genetic and diagnostic lab tests, beat its third-quarter targets as it agreed to a private-equity buyout. Total revenue grew 3% to $548 million, but by our math sales from businesses owned a year ago grew less than 1% once the acquired Parse Biosciences unit is stripped out. Profit per share excluding one-offs rose 7% to $0.65 on higher-margin chemical kits, U.S. tariff refunds and share buybacks. Because EQT Private Equity agreed to buy the company, management suspended its full-year outlook and cancelled its conference call.
| Sales from businesses owned a year ago | ~1% at constant currency, by our math (+3% including Parse) |
|---|---|
| Profit per share, excluding one-offs | $0.65 +7% from a year ago (plan was at least $0.62) |
| Operating margin, excluding one-offs | 30.4% +0.8 percentage points from a year ago |
| Full-year 2026 outlook | Withdrawn suspended during the €46.50 per share EQT takeover offer |
⚖️ Verdict: 🟢 Bullish
The story got better because the €10.8 billion cash takeover offer resolves a year-long chief executive vacancy and removes the risk of a painful medium-term target reset. New automated sample machines and early U.S. approvals for bloodstream infection panels also lifted core lab demand. One caution: tuberculosis testing stayed flat on weak U.S. immigration screening, and a federal jury found that Parse willfully infringed three rival patents.
The question now is whether the buyout closes smoothly in mid-2027 or hits regulatory and shareholder hurdles that force Qiagen back onto its standalone plan. If the deal closes, operational debates end; if it fails, the company faces a €150 million break fee and sub-1% underlying growth. Shareholder tender results and regulatory filings over the next two quarters will decide.
🐂 Bull Case
EQT Agrees to Buy Qiagen for €10.8 Billion
For a year, Qiagen operated without a permanent successor for departing chief executive Thierry Bernard while rumours of a sale grew. On October 21, the Dutch molecular testing group ended that uncertainty. A holding company controlled by EQT Private Equity agreed to "make an all-cash voluntary public takeover offer to acquire all outstanding QIAGEN shares at €46.50 per share".
The deal values the business at €10.8 billion, or about $12.1 billion including $1.1 billion of net debt. Both governing boards unanimously backed the agreement as "in the best interest of QIAGEN and its business". Because a private buyer is stepping in, the leadership vacuum and the risk of a painful strategy reset under a new chief executive no longer hang over operations.
What to watch: shareholder tender results and regulatory clearances ahead of the expected mid-2027 closing. The buyer needs at least 50% of issued shares plus one share and Extraordinary General Meeting approval to complete the takeover.
New Instruments and FDA Approvals Lift Core Lab Sales
Qiagen relies on new lab machines and test panels to drive second-half growth. That product rollout delivered in the third quarter. The company launched QIAmini, a compact automated sample-preparation machine for smaller labs, completing its rollout of three new systems this year. It also won U.S. clearance ahead of schedule for two bloodstream infection panels on QIAstat-Dx, its rapid diagnostic machine.
- Sample technologies sales: $187.4 million, up 10% at constant currency
- Sample technologies sales from businesses owned a year ago: up 3% at constant currency
- Sample technologies instrument sales: up about 10% at constant currency
- QIAstat-Dx diagnostic sales: $35 million, up 11% at constant currency
- Genomics and sequencing sales: $66.0 million, up 9% at constant currency
Sample technologies grew mainly because Qiagen bought Parse Biosciences, a single-cell research specialist, in December 2025. Qiagen said "Parse remains on track to exceed its 2026 sales target of approximately $40 million", which adds roughly 7 percentage points to the division's growth by our math.
What to watch: full-year instrument placement numbers for QIAsprint Connect and QIAsymphony Connect in the fourth-quarter report. Rising machine installations would confirm that labs will buy more chemical kits in 2027.
Consumables Mix and Tariff Refunds Lifted Operating Margin
Earlier this year, Qiagen expected its operating margin excluding one-offs to stay flat at 29.5% as it absorbed U.S. tariffs and research costs at Parse Biosciences. Instead, the operating margin excluding one-offs rose 0.8 percentage points from a year ago to 30.4%. Reported gross margin jumped 2.4 percentage points to 64.6% because the cost of making products fell from 37.8% of sales to 35.4%.
Two things drove the improvement. Chemical kits and software — which carry higher margins than lab machines — reached 91% of total revenue. Gross profit also benefited from "the impact of U.S. tariff refunds" and efficiency savings. Those gains easily covered a 0.7 percentage point rise in research and development spending, which reached 9.8% of sales as Qiagen funded Parse.
What to watch: gross margin excluding one-offs in the fourth quarter. A reading near 67% without further tariff refunds would show that efficiency gains and Parse kit sales are lifting profitability on their own.
🐻 Bear Case
Takeover Closes the Book on the 2026 and 2028 Targets
Qiagen highlighted that third-quarter sales grew 3% at constant currency, beating its 1% to 2% outlook. Yet "QIAGEN has suspended its 2026 outlook and will not provide financial guidance while the transaction is pending", and it cancelled its quarterly conference call. That leaves investors with no forward plan and no update on the 2028 targets.
The headline beat also relies on an acquisition. Excluding Parse Biosciences, which adds about $12 million of quarterly sales by our math, sales from businesses owned a year ago grew less than 1% at constant currency. Prior full-year plans required fourth-quarter sales growth to jump to between 5% and 8% at constant currency. If the takeover fails, Qiagen also warned it "may be required to pay the Bidder a termination payment of €150 million".
What to watch: fourth-quarter constant-currency sales growth in February 2027. A rate below 5% would show that the old full-year target would have missed without the takeover.
Tuberculosis Testing Stalls and PCR Sales Keep Falling
Outside of sample preparation and sequencing, demand in Qiagen's other product lines remains sluggish. QuantiFERON, its flagship blood test for latent tuberculosis that brings in a quarter of company revenue, stood still at $136 million. Qiagen said "continued softness in U.S. immigration testing was offset by demand in other latent tuberculosis (TB) testing groups".
Meanwhile, cautiously funded research labs continue to hold back on routine equipment and older kits. Total instrument revenue across the group rose just 1% at constant currency to $51.6 million. In the PCR division, which sells tools to copy and measure DNA, sales fell 5% at constant currency to $71.2 million. Strong demand for the newer QIAcuity digital PCR system could not make up for falling sales of older quantitative PCR kits, machines and third-party products.
What to watch: fourth-quarter QuantiFERON sales. After $380 million in the first nine months, the test needs $120 million in the fourth quarter to reach its $500 million full-year goal.
Restructuring Costs Double and Parse Loses a Patent Verdict
While profit excluding one-offs rose, reported net income fell 19% from a year ago to $105.7 million. Part of the drop came from taxes returning to 20.1% after a one-time U.S. tax deduction last year. The rest came from restructuring and integration charges, which more than doubled from $8.1 million to $19.2 million, or 3.5% of sales, as Qiagen relocated jobs under its $75 million cost programme.
Integration also brought a legal setback. In August 2026, a U.S. federal jury found that Parse Biosciences willfully infringed three single-cell patents held by Scale Biosciences and Roche, awarding $4.9 million in damages. Because infringement was willful, the judge can triple the penalty, adding up to $9.8 million. Qiagen recorded a $4.9 million reimbursement asset from the $28.8 million acquisition escrow account, so the verdict did not hit net income, but the ruling challenges Parse's intellectual property.
What to watch: the post-trial judgment in Delaware federal court. An injunction or a penalty enhancement beyond the escrow protection would hurt the return on the $231 million Parse purchase.
👓 Other Themes
China Demand Drags on Asia-Pacific Sales
Regional sales moved in opposite directions during the third quarter. Revenue rose 4% in the Americas to $298.3 million and 3% in Europe, the Middle East and Africa to $176.9 million. In contrast, sales in the Asia-Pacific, Japan and Rest of World region slipped 1% to $72.6 million because "challenging macro-demand trends in China" outweighed growth in Australia, Malaysia and Indonesia.
💲 Other KPIs
Free cash flow fell 10% from a year ago in the third quarter and 5% over the first nine months to $319 million. Cash flow slowed because Qiagen spent $35.3 million building inventory during the first nine months "in response to geopolitical conditions and to support new product launches", lifting balance-sheet inventory 6% since December to $320.0 million.
Net debt stood at $812.7 million by our math at the end of September, with $830.1 million in cash and short-term investments against $1.64 billion of total debt. Net debt to Ebitda excluding one-offs edged down from 1.1x in June to 1.0x, but remains above 0.7x at year-end 2025 after January's $496.7 million share repayment and July's $72.3 million dividend.
Diluted shares fell 4.8% from 218.5 million a year ago because the Dutch group completed a synthetic share buyback in January 2026 that combined a direct capital repayment with a 20-for-19 reverse stock split. The lower share count lifted third-quarter profit per share growth by about 5 percentage points above net profit growth.
🔮 Guidance
Withdrawn. Qiagen suspended its full-year sales outlook while the EQT Private Equity takeover offer is pending. Through the first nine months of 2026, net sales rose 2% as reported to $1.58 billion and were unchanged at constant exchange rates.
Withdrawn. The molecular diagnostics group also retracted its full-year earnings floor because of the takeover agreement. Over the first nine months, profit per share excluding one-offs rose 2% at constant currency to $1.80, after clearing the quarterly floor for at least six straight quarters.
❓ Key Questions
How much did U.S. tariff refunds add to margin?
The quarterly report credits U.S. tariff refunds for part of the 2.4 percentage point jump in gross margin, without giving the dollar figure. Knowing the refund size would show how much of the 30.4% operating margin excluding one-offs is repeatable.
What is the exposure to triple damages at Parse?
A federal jury found Parse Biosciences willfully infringed three patents, which allows the judge to triple the $4.9 million damages award to $14.7 million. Investors need to know if the acquisition escrow covers enhanced damages and whether an injunction is possible.
How many new automation systems were placed in Q3?
Sample technologies instrument sales rose 10% at constant currency following the launches of QIAsprint Connect, QIAsymphony Connect and QIAmini. Qiagen previously promised placement counts at year-end, and cancelling the conference call left third-quarter installation numbers undisclosed.
Which regulator poses the longest review for EQT's offer?
Closing is scheduled for mid-2027, roughly eight months away, and requires antitrust and foreign-investment approvals alongside a 50% plus one share tender threshold. Management has not detailed which jurisdiction sets that timeline.